WALTHAM, Mass. A new report by Decision Resources found that an angiogenesis inhibitor will garner sales of $640 million in less than 10 years, succeeding its current competition.
In their new report, entitled "Renal Cell Carcinoma", Decision Resources finds that Votrient will overtake Sutent as the renal cell carcinoma market leader by 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. In 2008, Sutent had accounted for 61% of sales in the angiogenesis inhibitor drug class.
Additionally the angiogenesis inhibitor drug class will continue to dominate this market over the next decade, capturing 87% of total sales in 2018, according to the report.
"Thought leaders we interviewed indicate that they are optimistic about several emerging therapies, most notably axitinib and Votrient," said Decision Resources analyst Karen Pomeranz, M.Sc., Ph.D. "One expert called axitinib 'the most exciting' emerging agent in renal cell carcinoma in recent years and another thought leader said that Votrient's clinical efficacy is comparable to that of Sutent and that Votrient has a more favorable side-effect profile than Sutent."
Meanwhile, the report also finds that Novartis's Afinitor and Pfizer's axitinib will surpass Bayer Healthcare/Onyx's Nexavar and Wyeth's Torisel by 2018 in the second- and third-line treatment settings. In 2008, Nexavar was the leading therapy in the second-line setting and Torisel was the leading therapy in the third-line setting for the treatment of renal cell carcinoma.